MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

MC

498.85

-0.03%↓

NDA.FI

11.79

+0.94%↑

DIM

201.7

+0.35%↑

Search

DBV Technologies SA

Open

1.496 -1.97

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.44

Max

1.556

Belangrijke statistieken

By Trading Economics

Inkomsten

7.4M

-23M

EPS

-0.215

Winstmarge

-2,852.369

Werknemers

109

EBITDA

5.8M

-23M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+289.61% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

13M

193M

Vorige openingsprijs

3.47

Vorige sluitingsprijs

1.496

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

DBV Technologies SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 dec 2024, 23:55 UTC

Populaire aandelen

Stocks to Watch: Adobe, Champions Oncology, DBV Technologies

22 okt 2024, 21:37 UTC

Belangrijke Marktbewegers

DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch

Peer Vergelijking

Prijswijziging

DBV Technologies SA Prognose

Koersdoel

By TipRanks

289.61% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 6 EUR  289.61%

Hoogste 6 EUR

Laagste 6 EUR

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor DBV Technologies SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

1.246 / N/ASteun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.